PT - JOURNAL ARTICLE AU - Owen, Dafydd R. AU - Allerton, Charlotte M. N. AU - Anderson, Annaliesa S. AU - Aschenbrenner, Lisa AU - Avery, Melissa AU - Berritt, Simon AU - Boras, Britton AU - Cardin, Rhonda D. AU - Carlo, Anthony AU - Coffman, Karen J. AU - Dantonio, Alyssa AU - Di, Li AU - Eng, Heather AU - Ferre, RoseAnn AU - Gajiwala, Ketan S. AU - Gibson, Scott A. AU - Greasley, Samantha E. AU - Hurst, Brett L. AU - Kadar, Eugene P. AU - Kalgutkar, Amit S. AU - Lee, Jack C. AU - Lee, Jisun AU - Liu, Wei AU - Mason, Stephen W. AU - Noell, Stephen AU - Novak, Jonathan J. AU - Obach, R. Scott AU - Ogilvie, Kevin AU - Patel, Nandini C. AU - Pettersson, Martin AU - Rai, Devendra K. AU - Reese, Matthew R. AU - Sammons, Matthew F. AU - Sathish, Jean G. AU - Singh, Ravi Shankar P. AU - Steppan, Claire M. AU - Stewart, Al E. AU - Tuttle, Jamison B. AU - Updyke, Lawrence AU - Verhoest, Patrick R. AU - Wei, Liuqing AU - Yang, Qingyi AU - Zhu, Yuao TI - An Oral SARS-CoV-2 M<sup>pro</sup> Inhibitor Clinical Candidate for the Treatment of COVID-19 AID - 10.1101/2021.07.28.21261232 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.28.21261232 4099 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261232.short 4100 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261232.full AB - The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become an established global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to counter the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity, and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse- adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency, in a phase I clinical trial in healthy human participants.ClinicalTrials.gov Identifier: NCT04756531One-Sentence Summary PF-07321332 is disclosed as a novel, orally active, investigational small-molecule inhibitor of the SARS-CoV-2 main protease, which is being evaluated in clinical trials for the treatment of COVID-19.Competing Interest StatementDRO, CMNA, ASA, LA, MA, SB, BB, RDC, AC, KJC, AD, LD, HE, RF, KSG, SEG, EPK, ASK, JCL, JL, WL, SN, RSO, KO, NCP, DKR, MRR, MFS, JGS, RPS, CMS, AS, JBT, LU, PRV, LW, QY, YZ are employees of Pfizer and some of the authors are shareholders in Pfizer Inc. SWM, JJN, MP were employees of Pfizer Inc. during part of this study.Clinical TrialNCT04756531Funding StatementThis study was sponsored by Pfizer, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ADVARRA/IntegReview Ethical Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon request and subject to certain criteria, conditions and exceptions, Pfizer will provide access to de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices for indications that have been approved in the US and/or the EU or in programs that have been terminated (i.e., development of all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, requestors must enter into a data access agreement with Pfizer.